Chris Ryan

Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Will the FDA approve bezuclastinib for the treatment of patients with nonadvanced systemic mastocytosis?

Venetoclax plus decitabine/cedazuridine after a venetoclax-based RIC regimen was effective and safe in myelodysplastic syndromes or acute myeloid leukemia.

The EMA has received a Type II variation application seeking the approval of teclistamab for relapsed/refractory multiple myeloma after 1 line of therapy.

Data from China showed relma-cel yielded durable responses in patients with relapsed/refractory mantle cell lymphoma.

Mezigdomide plus carfilzomib and dexamethasone improved progression-free survival in relapsed/refractory multiple myeloma.

Giredestrant plus palbociclib did not yield a statistically significant PFS improvement in ER-positive/HER2-negative locally advanced or metastatic breast cancer.

Zovegalisib plus fulvestrant drove responses in HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

Allo-HSCT did not improve survival outcomes in patients with lower-risk myelodysplastic syndrome who had some higher-risk features.

Will the FDA approve rusfertide for the treatment of adult patients with polycythemia vera?

In an OncLive Ask the Expert program, Sagar Lonial, MD, FACP, FASCO, outlined how CELMoDs may be integrated into multiple myeloma care.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

Gurbakhash Kaur, MD, discusses the exploration of CELMoDs in multiple myeloma care and how they may affect the treatment paradigm.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

An analysis showed the manufacturing and distribution of Orca-T was consistent for patients with hematologic malignancies.

Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS.

An ML-NMR analysis associated zanubrutinib with PFS improvements vs ibrutinib or acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses 4-year data from the PATHFINDER trial of avapritinib in advanced systemic mastocytosis.

Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.

Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.

Orca-T was associated with OS, RFS, and NRM improvements in patients with hematologic malignancies who also received myeloablative conditioning.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

Cilta-cel was linked with low progression events and a potential cure fraction in relapsed/refractory multiple myeloma.

Part 2 of the ongoing phase 2/3 HARBOR study is evaluating elenestinib in patients with indolent systemic mastocytosis.

Mabel Mardones, MD, discusses implications of data for Dato-DXd and sacituzumab govitecan in frontline metastatic triple-negative breast cancer.

Tagraxofusp was well tolerated and yielded modest efficacy signals as monotherapy in myelofibrosis.

Marc J. Braunstein, MD, PhD, details the significance of the FDA approval of daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

WJ01024 alone and in combination with ruxolitinib was safe and generated efficacy signals in relapsed/refractory myelofibrosis.